New strategies to target Bcr-Abl with ATP-competitive and allosteric inhibitors

被引：0
|
作者：
Hantschel, O. [1 ]
机构：
[1] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res ISREC, Lausanne, Switzerland
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：199 / 199
页数：1
相关论文
共 50 条
  • [41] Design of Selective, ATP-Competitive Inhibitors of Akt
    Freeman-Cook, Kevin D.
    Autry, Christopher
    Borzillo, Gary
    Gordon, Deborah
    Barbacci-Tobin, Elsa
    Bernardo, Vincent
    Briere, David
    Clark, Tracey
    Corbett, Matthew
    Jakubczak, John
    Kakar, Shefali
    Knauth, Elizabeth
    Lippa, Blaise
    Luzzio, Michael J.
    Mansour, Mahmoud
    Martinelli, Gary
    Marx, Matthew
    Nelson, Kendra
    Pandit, Jayvardhan
    Rajamohan, Francis
    Robinson, Shaughnessy
    Subramanyam, Chakrapani
    Wei, Liuqing
    Wythes, Martin
    Morris, Joel
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (12) : 4615 - 4622
  • [42] Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation
    Shimokawa, Kenichiro
    Shibata, Norihito
    Sameshima, Tomoya
    Miyamoto, Naoki
    Ujikawa, Osamu
    Nara, Hiroshi
    Ohoka, Nobumichi
    Hattori, Takayuki
    Cho, Nobuo
    Naito, Mikihiko
    ACS MEDICINAL CHEMISTRY LETTERS, 2017, 8 (10): : 1042 - 1047
  • [43] Characterization of both allosteric and ATP-competitive kinase inhibitors with TR-FRET binding assays
    Fakhoury, Stephen A.
    Lebakken, Connie
    Marks, Bryan
    Wolken, Jill K.
    Riddle, Steven M.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 239
  • [44] Molecular Dynamics Simulations of p97 Including Covalent, Allosteric and ATP-Competitive Inhibitors
    Rendine, Stefano
    Orrenius, Christian
    Dapiaggi, Federico
    Pieraccini, Stefano
    Motto, Ilaria
    D'Alessio, Roberto
    Magnaghi, Paola
    Isacchi, Antonella
    Felder, Eduard
    Sironi, Maurizio
    ACTA CHIMICA SLOVENICA, 2019, 66 (02) : 395 - 401
  • [45] New BCR-ABL inhibitors overcome resistance to STI-571
    Hitt, E
    LANCET ONCOLOGY, 2001, 2 (12): : 713 - 713
  • [46] Characterization of both allosteric and ATP-Competitive kinase inhibitors with TR-FRET binding assays
    Lebakken, Connie
    Riddle, Steve
    Marks, Bryan
    Singh, Upinder
    Frazee, Jack
    Eliason, Hildegard
    Wolken, Jill
    Gao, Yi
    Reichling, Laurie
    Vogel, Kurt
    CANCER RESEARCH, 2009, 69
  • [47] AKT2 gene amplification is a marker for sensitivity to allosteric but not ATP-competitive AKT inhibitors
    Abe, T.
    Ichikawa, K.
    Fujita, R.
    Okada, M.
    Tanaka, K.
    Ohkubo, M.
    Yonekura, K.
    Shimomura, T.
    Utsugi, T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 120 - 120
  • [48] The role of structure and biophysics in the discovery of allosteric kinase inhibitors: ABL001, a potent and specific inhibitor of BCR-ABL
    Cowan-Jacob, Sandra W.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2016, 72 : S4 - S5
  • [49] Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML
    Weisberg, E.
    Deng, X.
    Choi, H. G.
    Barrett, R.
    Adamia, S.
    Ray, A.
    Moreno, D.
    Kung, A. L.
    Gray, N.
    Griffin, J. D.
    LEUKEMIA, 2010, 24 (07) : 1375 - 1378
  • [50] Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML
    E Weisberg
    X Deng
    H G Choi
    R Barrett
    S Adamia
    A Ray
    D Moreno
    A L Kung
    N Gray
    J D Griffin
    Leukemia, 2010, 24 : 1375 - 1378
12345